Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment
Open accessAbstract
Parkinson's disease (PD) is one of the most common neurodegenerative diseases worldwide. Besides characteristic PD motor features, the disease has important non-motor characteristics such as cognitive impairment. The role of genetic factors in cognitive impairment associated with PD is still unclear. In this study, we examined whether BDNF Val66Met was associated with impaired cognition in Parkinson's disease. One hundred and seventy five patients with a clinical diagnosis of Parkinson's disease were included. Global cognitive abilities of the patients were measured by the Mini-Mental State Examination (MMSE). Poisson Regression models were used to test for association between 66Met carriers and cognitive impairment controlling for covariates. Carriers of at least one BDNF 66Met allele presented a higher prevalence of cognitive impairment (p=0.005 RR=1.45 IC=95% [1.1-1.8]). These results suggest a role for BDNF Val66Met polymorphism on cognitive impairment in PD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The BDNF Val66Met polymorphism is associated with cognitive processes and cognitive impairment in neurodegenerative disease such as Parkinson's disease and Alzheimer's disease, and with several brain disorders including MDD, bipolar disorder, epilepsy, schizophrenia, aging and dementia, and stroke.
“More specifically, BDNF Val66Met polymorphism is associated with cognitive processes [112,123,124,125,126,127], and cognitive impairment in neurodegenerative disease, such as Parkinson’s disease (PD) [128,129] and AD [130,131], and even more with several brain disorders, including MDD and bipolar disorder [132,133,134,135,136,137], epilepsy [138,139,140], schizophrenia [125,141,142,143,144], aging”
From Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer (2020) · cites this paper as [128]
Cites
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027 · see citing works
Longitudinal study of normal cognition in Parkinson disease
Pigott, K., Rick, J., Xie, S. X., Hurtig, H., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Chahine, L. M., Dahodwala, N., Akhtar, R. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002001 · Cited by 251 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Colucci-D’Amato, L., Speranza, L., & Volpicelli, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207777 · Cited by 991 · see citing works
Wang, Q., Liu, J., Guo, Y., Dong, G., Zou, W., & Chen, Z. (2019) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198443 · Cited by 45 · see citing works
Influence of BDNF genetic polymorphisms in the pathophysiology of aging-related diseases
Urbina-Varela, R., Soto-Espinoza, M. I., Vargas, R., Quiñones, L., & del Campo, A. (2020) · Aging and disease · doi:10.14336/ad.2020.0310 · Cited by 27 · see citing works
- Authors
- Altmann, V., Schumacher-Schuh, A. F., Rieck, M., Callegari-Jacques, S. M., Rieder, C. R. M., & Hutz, M. H.
- Affiliations
- Universidade Federal do Rio Grande do Sul (BR)
- Corresponding author
- Hutz, Mara H.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 615
- Pages
- 88-91
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2274814543
- Cited by
- 43
- References
- 2
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 11 · 2017: 1 · 2016: 5
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, cognitive impairment, BDNF Val66Met polymorphism, brain-derived neurotrophic factor, genetic susceptibility, non-motor symptoms, Mini-Mental State Examination
- MeSH terms
- Aged, Cognition Disorders, Female, Humans, Male, Middle Aged, Parkinson Disease, Polymorphism, Genetic, Brain-Derived Neurotrophic Factor, Genetic Association Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
